Don’t risk using Andarine

20 December 2019

Clinical trials on the Selective Androgen Receptor Modulator (SARM) Andarine (S4) have been discontinued and it is not approved for human use.

SARMs are experimental medicines which claim to build muscle mass and bone density and are said to have fewer side effects than similar products such as steroids.

However, according to the Therapeutic Goods Administration (TGA), SARMs are risky to use because they haven't been approved for human use, are still being researched and may have unknown health risks.

“Because research into SARMs for human use is limited, the full risk of using SARMs has not been established, especially the possible long-term impact on health,” the TGA warns.

“There is limited information on how SARMs interact with other medications or conditions, and no official guidance on appropriate dosage.”

SARMs have been associated with adverse effects on liver, heart and eye sight, such as altered perception and colours.

Initially developed to treat conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, Andarine is covered by the Poisons Standard. Access to it without authority is illegal, and in some cases may result in fines and/or jail time.

Andarine, which is prohibited at all times for athletes, has been detected in athletes internationally, one in 2016, three in 2017, while 2018 figures are yet to be publicly released.

For more on SARMs, visit: https://www.tga.gov.au/blogs/tga-topics/consumer-story-tim-and-selective-androgen-receptor-modulators-sarms